

SUPPLEMENTARY MATERIAL

Regulation of the p38-MAPK pathway by hyperosmolarity and by WNK kinases

Zetao Liu^{1,2}, Wael Demian^{1,2}, Avinash Persaud¹, Arohan R. Subramanaya³, Daniela Rotin^{1,2,*}

¹Cell Biology Program, the Hospital for Sick Children, and ²Biochemistry Department, University of Toronto, Canada, ³Department of Medicine and Cell Biology, University of Pittsburgh, USA

Running title: p38-MAPK regulation by hyperosmolarity and by WNKs

*Correspondence: Dr. Daniela Rotin, The Hospital for Sick Children, Cell Biology Program, PGCRL 19-9715, 686 Bay St., Toronto, Ontario, Canada, M5G 0A4

SUPPLEMENTARY TABLES

Table S1. Key resources of chemical, reagents and antibodies

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Mouse anti-SPAK (STK39)	Thermo-Fisher	Cat# MA5-24935
Mouse anti- β -actin	Sigma-Aldrich	Cat# A2228; RRID:AB_47669
Mouse anti-phospho-p38 MAPK (T180/Y182)	BD Bioscience	Cat# 612280; RRID:AB_399597
Mouse anti-vinculin	Santa Cruz	Cat# sc-25336; RRID:AB_628438
Rabbit anti-NKCC1	Cell Signaling	Cat# D13A9; RRID:AB_10830068
Rabbit anti-phospho-SPAK antibody (Ser-373)/phospho-OSR1 antibody (Ser-325)	EMD Millipore	Cat# 07-2273
Rabbit anti-phospho-MKK3 (Ser189)/MKK6 (Ser207)	Cell Signaling	Cat# 9231
Rabbit anti-phospho-SEK1/MKK4 (Ser257/Thr261)	Cell Signaling	Cat# 9156
Rabbit anti-phospho-ASK1 (Thr845) Antibody	Cell Signaling	Cat# 3765
Rabbit anti-p38 MAPK	Cell Signaling	Cat# 9212; AB_330713
Rabbit anti-GAPDH	Cell Signaling	Cat# 2118
Rabbit anti-phospho-MAPKAPK-2 (p-MK2) (Thr334)	Cell Signaling	Cat# 3007
Rabbit anti-WNK1	Cell Signaling	Cat# 4979
Rabbit anti-phospho-TRAF2 (Ser11)	Cell Signaling	Cat# 13908
Rabbit anti-TRAF2	Cell Signaling	Cat# 4724
Rabbit anti-phospho-TAK1 (Ser412)	Cell Signaling	Cat# 9339
Rabbit anti-TAK1	Cell Signaling	Cat# 5206
Rabbit anti-phospho-p70 S6 Kinase (Thr389)	Cell Signaling	Cat# 9205
Mouse anti-p70 S6 Kinase	Santa Cruz	Cat# SC-8418
Chemicals, Peptides, and Recombinant Proteins		
SB203580	SelleckChem	Cat# S1076
Monensin	Sigma-Aldrich	Cat# M5273
Wnk463	SelleckChem	Cat# S8358
5-(N-Ethyl-N-isopropyl) amiloride (EIPA)	Sigma-Aldrich	Cat# 1154-25-2
Gramicidin A	Sigma-Aldrich	Cat# 11029-61-1
Puromycin	Bioshop	Cat# PUR333
GS-444217	MedKoo Biosciences	Cat# 564706
5Z-7-Oxozeaenol	Tocris	Cat# 3604
NSC23766	Tocris	Cat# 2161
Cariporide	Tocris	Cat# 5358
Advanced DMEM/F-12	Thermo Fisher	Cat# 12634028
Intesticult Organoid Growth Medium (mouse)	Stem Cell	Cat# 06005
Corning Matrigel	Corning	Cat# 356231
Plasmids		
pcDNA3.1-MAP3K5 (ASK1) WT	Addgene	Plasmid#: 47104
pcDNA3 HA-humanTRAF2	Addgene	Plasmid#: 66932


pEBB-3XMyC-TRAF2	Addgene	Plasmid#: 44104
pEBB-3XMyC-TRAF2 S11A	Addgene	Plasmid#: 44105
Experimental Models: Cell Lines		
HeLa	ATCC	Cat#CCL-2
HEK293	ATCC	Cat#CRL-1573
MDCK	ATCC	Cat#CCL-34
Human Primary Bronchial Epithelial Cells	Abm	Cat# T4006
Scramble Control KD HeLa	(14)	
NKCC1 KD HeLa	(14)	
Recombinant DNA		
pGIPZ human TNFR1 shRNA	Dharmacon	V2LHS 94071
pGIPZ human WNK1 shRNA	Dharmacon	V3LHS 638999
pGIPZ scramble shRNA	Dharmacon	RHS4348
Software and Algorithms		
Syngistix	PerkinElmer	N/A
Prism	GraphPad	N/A
Image StudioVersion 3.1.4	Li-Cor	N/A

Table S2. Osmotic solutions used in western blot experiments, intracellular Na⁺ or K⁺ concentration measurements and cell proliferation assays.

Condition	Iso-osmotic	Hyperosmotic
NaCl solutions	315 mOsm: 135 mM NaCl, 2.5 mM KCl, 0.25 mM CaCl ₂ , 0.25 mM MgCl ₂ , 5 mM glucose, 15 mM Hepes, pH 7.4	400 mOsm: 180 mM NaCl, 3.33 mM KCl, 0.25 mM CaCl ₂ , 0.25 mM MgCl ₂ , 5 mM glucose, 15 mM Hepes, pH 7.4 475 mOsm: 225 mM NaCl, 4.16 mM KCl, 0.25 mM CaCl ₂ , 0.25 mM MgCl ₂ , 5 mM glucose, 15 mM Hepes, pH 7.4 580 mOsm: 270 mM NaCl, 5 mM KCl, 0.25 mM CaCl ₂ , 0.25 mM MgCl ₂ , 5 mM glucose, 15 mM Hepes, pH 7.4
NMDG-Cl solutions	315 mOsm: 135 mM NMDG-Cl, 2.5 mM KCl, 0.25 mM CaCl ₂ , 0.25 mM MgCl ₂ , 5 mM glucose, 15 mM Hepes, pH 7.4	400 mOsm: 180 mM NMDG-Cl, 3.33 mM KCl, 0.25 mM CaCl ₂ , 0.25 mM MgCl ₂ , 5 mM glucose, 15 mM Hepes, pH 7.4 475 mOsm: 225 mM NMDG-Cl, 4.16 mM KCl, 0.25 mM CaCl ₂ , 0.25 mM MgCl ₂ , 5 mM glucose, 15 mM Hepes, pH 7.4 580 mOsm: 270 mM NMDG-Cl, 5 mM KCl, 0.25 mM CaCl ₂ , 0.25 mM MgCl ₂ , 5 mM glucose, 15 mM Hepes, pH 7.4
Na-Gluconate solutions	315 mOsm: 135 mM Na-Gluconate, 2.5 mM Kgluconate, 0.25 mM CaCl ₂ , 0.25 mM MgCl ₂ , 5 mM glucose, 15 mM Hepes, pH 7.4	580 mOsm: 270 mM Na-Gluconate, 5 mM K-gluconate, 0.25 mM CaCl ₂ , 0.25 mM MgCl ₂ , 5 mM glucose, 15 mM Hepes, pH 7.4
Cellular Medium	315 mOsm: DMEM + 10% FBS	475 mOsm: DMEM + 10% FBS + 90 mM NaCl


(A) HeLa cells were treated with Iso- or hyper- osmotic Choline-Cl solutions for 15 minutes. **(B)** HeLa cells were treated with an increasing concentration of NSC23766 (Rac1 inhibitor) for 2 hours followed by incubation with hyper-osmotic NaCl solution in the absence/presence of NSC23766. **(C)** HeLa cells were treated with iso-osmotic or hyper-osmotic NaCl solutions for 15 minutes. **(D)** Human Primary Bronchial Epithelial cells, or **(E)** Mouse Colonic Organoids, were treated with 10 μ M WNK463 for 2 hours followed by incubation with iso- or hyper- osmotic NaCl for 15 minutes in the absence/presence of

WNK463. Quantification of active p38 (p-p38) or MKK4 (p-MKK4) is depicted below their respective blots. All data are mean $\pm$ s.e.m, N $\geq$ 3 independent experiments. Statistics as described in Figure 1.



Supplementary Figure 2. Cell volume changes in the first 5 minutes of the RVI experiments.

Cell volume changes in the first 5 minutes of the respective RVI experiments shown in Figures 5 and 6. p38 inhibition for (A) 2 days or (B) 2 hours; ASK1 inhibition for (C) 2 days or (D) 2 hours; TAK1 inhibition for (E) 2 days or (F) 2 hours; (G) WNK inhibition with or without 30 minutes NHE1 inhibition; (H) WNKs inhibition for 2 hours; (I) NHE1 inhibition for 30 minutes; (J) WNKs and p38 inhibition for 2 days; (K) HeLa scramble control (SC) or WNK1 knockdown (KD) cells; (L) HeLa scramble control (SC) or NKCC1 KD cells. Cell volume was measured by using a Coulter counter. All data are mean $\pm$ s.e.m, $N \geq 3$ independent experiments.



Supplementary Figure 3

Supplementary Figure 3. Regulatory Volume Increase (RVI) of HeLa cells exposed to hypo-osmotic solution before hyper-osmotic shock, or treated with short-term p38, ASK1, TAK1, WNKs or NHE1 inhibitors.

(A) HeLa Scramble control (SC) cells were treated (or not) with hypo-osmotic NaCl solution for 10 minutes prior to switching to iso- or hyper-osmotic NaCl solution to analyze RVI. **(B-E)**: 2 hours inhibition prior to measuring RVI under iso- or hyper-osmotic NaCl solution in the absence/presence of: **(B)** 5 μ M SB203580 (p38 inhibitor), **(C)** 10 μ M GS-444217 (ASK1 inhibitor), **(D)** 1 μ M 5Z-7-Oxozeaenol (TAK1 inhibitor), **(E)** 10 μ M WNK463 (pan-WNKs inhibitor). **(F)** 10 μ M of Cariporid (NHE1 inhibitor) applied for 30 minutes. **(G)** HeLa scramble control (SC) or WNK1 KD cells were washed with PBS and exposed to iso- or hyper-osmotic solutions for the indicated times. Cell volume recovery (RVI) was measured as above. All data are mean $\pm$ s.e.m, N $\geq$ 3 independent experiments.